Publications by authors named "Arumugam Poornima"

It takes an average of 10-15 years to uncover and develop a new drug, and the process is incredibly time-consuming, expensive, difficult, and ineffective. In recent years the dramatic changes in the field of artificial intelligence (AI) have helped to overcome the challenges in the drug discovery pipeline. Artificial intelligence (AI) has taken root in various pharmaceutical sectors, from lead compound identification to clinical trials.

View Article and Find Full Text PDF

As triple negative breast cancer (TNBC) lacks a specific target, exploration of abnormally expressed genes during the progression of TNBC is important for a better understanding of tumorigenesis and to find a specific target. We intended to figure out genes associated with TNBC, which can provide unique insights into gene dysregulation in TNBC while also pointing to new possible therapeutic targets for TNBC. A meta-analysis of multiple TNBC mRNA profiles was performed to identify consistently differentially expressed genes (CDGs).

View Article and Find Full Text PDF

The heterogeneity and poor prognosis of triple-negative breast cancer (TNBC) have limited the treatment options and made clinical management challenging. This has nurtured a major effort to discover druggable molecular targets. Currently, chemotherapy is the primary treatment strategy for this disease.

View Article and Find Full Text PDF

Background: In the current era, the development of molecular techniques involves nano techniques, and the synthesis of nanoparticles is considered the preferred field in nanotechnology.

Objective: The aim of the present work is to analyze the anticancer activity of the thymoquinone conjugated ZnO nanoparticles and understand its mechanism of action in triple-negative breast cancer cell lines MDA-MB-231.

Methods: Zinc Oxide (ZnO) nanoparticles have extensive applications, and it was synthesized using a chemical precipitation method.

View Article and Find Full Text PDF